The DOI matches its Crossref record; 152 of the 152 references it cites were found in a registry or an index.
Vascular Endothelial Growth Factor Receptor (VEGFR-2)/KDR Inhibitors: Medicinal Chemistry Perspective
Open accessAbstract
New blood vessels formation from the existing vasculature is called angiogenesis. It is an essential physiological process for the growth of cells, tissue repair, wound healing, and reproductive system of females. The process of angiogenesis regulation is related to diseases such as rheumatism arthritis, diabetes, atherosclerosis, and cancer. The growth and metastasis of the tumor is directly depend on the process of tumor angiogenesis. Tumor angiogenesis is regulated by the proangiogenic factors and anti-angiogenic factors formed by the host cells as well as the tumor cells. Among various growth factors, namely VEGFs, PDGFs, FGFs, and cytokines; VEGFs and its receptor VEGFR-2 (KDR) have a significant impact on the process of angiogenesis. After the activation initiated, KDR undergoes autophosphorylation that ultimately leads to a proliferation of the endothelial cells, tumor angiogenesis, tumor growth, and metastasis. VEGFR-2 overexpression is observed in different kinds of cancer, namely breast cancer, cervical cancer, non-small cell lung cancer, hepatocellular carcinoma, renal carcinoma, and likewise. Over the past decade, several VEGFR-2 inhibitors have been developed. Angiogenesis inhibition by blocking the VEGFR-2 is an emerging strategy to develop selective and specific anticancer agents. The review articles published before were based on the structure and biology of VEGFR-2 rather than medicinal chemistry. While the emphasis of the current review article is to summarise, the recent advancement regarding VEGFR-2 inhibitors concerning medicinal chemistry approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., & Thun, M. J. (2008) · CA: A Cancer Journal for Clinicians · doi:10.3322/ca.2007.0010 · Cited by 10,188
The protein kinase complement of the human genome
Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002) · Science · doi:10.1126/science.1075762 · Cited by 8,145
Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
Shweiki, D., Itin, A., Soffer, D., & Keshet, E. (1992) · Nature · doi:10.1038/359843a0 · Cited by 4,617
The Biology of Vascular Endothelial Growth Factor
Ferrara, N., & Davis-Smyth, T. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.1.0287 · Cited by 4,330
Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1
Forsythe, J. A., Jiang, B.-H., Iyer, N. V., Agani, F., Leung, S. W., Koos, R. D., & Semenza, G. L. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.9.4604 · Cited by 3,981
Blume-Jensen, P., & Hunter, T. (2001) · Nature · doi:10.1038/35077225 · Cited by 3,738
VEGF receptor signalling ? in control of vascular function
Olsson, A.-K., Dimberg, A., Kreuger, J., & Claesson-Welsh, L. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1911 · Cited by 3,122
Pàez-Ribes, M., Allen, E., Hudock, J., Takeda, T., Okuyama, H., Viñals, F., Inoue, M., Bergers, G., Hanahan, D., & Casanovas, O. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.027 · Cited by 2,339
Batchelor, T. T., Sorensen, A. G., di Tomaso, E., Zhang, W.-T., Duda, D. G., Cohen, K. S., Kozak, K. R., Cahill, D. P., Chen, P.-J., Zhu, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.11.021 · Cited by 1,769
The Conformational Plasticity of Protein Kinases
Huse, M., & Kuriyan, J. (2002) · Cell · doi:10.1016/s0092-8674(02)00741-9 · Cited by 1,752
Shibuya, M. (2011) · Genes & Cancer · doi:10.1177/1947601911423031 · Cited by 1,748
Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
Ebos, J. M. L., Lee, C. R., Cruz-Munoz, W., Bjarnason, G. A., Christensen, J. G., & Kerbel, R. S. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.021 · Cited by 1,709
Signal transduction by vascular endothelial growth factor receptors
Koch, S., Tugues, S., Li, X., Gualandi, L., & Claesson-Welsh, L. (2011) · Biochemical Journal · doi:10.1042/bj20110301 · Cited by 1,635
Casanovas, O., Hicklin, D. J., Bergers, G., & Hanahan, D. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.09.005 · Cited by 1,621
Clinical translation of angiogenesis inhibitors
Kerbel, R., & Folkman, J. (2002) · Nature Reviews Cancer · doi:10.1038/nrc905 · Cited by 1,517
Mechanisms and regulation of endothelial VEGF receptor signalling
Simons, M., Gordon, E., & Claesson-Welsh, L. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.87 · Cited by 1,498
Yakes, F. M., Chen, J., Tan, J., Yamaguchi, K., Shi, Y., Yu, P., Qian, F., Chu, F., Bentzien, F., Cancilla, B., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0264 · Cited by 1,336
Lymphangiogenesis in development and human disease
Alitalo, K., Tammela, T., & Petrova, T. V. (2005) · Nature · doi:10.1038/nature04480 · Cited by 1,285
Rational design of inhibitors that bind to inactive kinase conformations
Liu, Y., & Gray, N. S. (2006) · Nature Chemical Biology · doi:10.1038/nchembio799 · Cited by 1,094
Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis
Shibuya, M., & Claesson-Welsh, L. (2006) · Experimental Cell Research · doi:10.1016/j.yexcr.2005.11.012 · Cited by 1,062
Takahashi, H., & Shibuya, M. (2005) · Clinical Science · doi:10.1042/cs20040370 · Cited by 953
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib
Kwak, E. L., Sordella, R., Bell, D. W., Godin-Heymann, N., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Driscoll, D. R., Fidias, P., Lynch, T. J., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502860102 · Cited by 952
Rousseau, S., Houle, F., Landry, J., & Huot, J. (1997) · Oncogene · doi:10.1038/sj.onc.1201380 · Cited by 845
Kornev, A. P., Haste, N. M., Taylor, S. S., & Ten Eyck, L. F. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607656103 · Cited by 762
Quinn, T. P., Peters, K. G., De Vries, C., Ferrara, N., & Williams, L. T. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.16.7533 · Cited by 754
Takahashi, T. (2001) · The EMBO Journal · doi:10.1093/emboj/20.11.2768 · Cited by 749
Molecular mechanisms of lymphangiogenesis in health and disease
Alitalo, K., & Carmeliet, P. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00051-x · Cited by 734
Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side Effects
Hartmann, J., Haap, M., Kopp, H.-G., & Lipp, H.-P. (2009) · Current Drug Metabolism · doi:10.2174/138920009788897975 · Cited by 630
Crawford, Y., Kasman, I., Yu, L., Zhong, C., Wu, X., Modrusan, Z., Kaminker, J., & Ferrara, N. (2009) · Cancer Cell · doi:10.1016/j.ccr.2008.12.004 · Cited by 611
Ikeda, E., Achen, M. G., Breier, G., & Risau, W. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.34.19761 · Cited by 594
Abramsson, A., Lindblom, P., & Betsholtz, C. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18549 · Cited by 562
Fujio, Y., & Walsh, K. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.23.16349 · Cited by 553
Receptor tyrosine kinases: mechanisms of activation and signaling
Hubbard, S. R., & Miller, W. T. (2007) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2007.02.010 · Cited by 531
Matsui, J., Funahashi, Y., Uenaka, T., Watanabe, T., Tsuruoka, A., & Asada, M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5270 · Cited by 530
VEGF Receptor Signaling in Tumor Angiogenesis
McMahon, G. (2000) · The Oncologist · doi:10.1634/theoncologist.5-2004-3 · Cited by 519
Through the “Gatekeeper Door”: Exploiting the Active Kinase Conformation
Zuccotto, F., Ardini, E., Casale, E., & Angiolini, M. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901443h · Cited by 518
Benjamin, L. E., & Keshet, E. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.16.8761 · Cited by 506
Plate, K. H., Breier, G., Millauer, B., Ullrich, A., & Risau, W. (1993) · PubMed · Cited by 498
Kopetz, S., Hoff, P. M., Morris, J. S., Wolff, R. A., Eng, C., Glover, K. Y., Adinin, R., Overman, M. J., Valero, V., Wen, S., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.8252 · Cited by 485
Abedi, H., & Zachary, I. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.24.15442 · Cited by 471
Effect of p53 Status on Tumor Response to Antiangiogenic Therapy
Yu, J. L., Rak, J. W., Coomber, B. L., Hicklin, D. J., & Kerbel, R. S. (2002) · Science · doi:10.1126/science.1068327 · Cited by 426
Sunitinib: A VEGF and PDGF receptor protein kinase and angiogenesis inhibitor
Roskoski, R. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.02.156 · Cited by 412
The Restriction Point of the Cell Cycle
Blagosklonny, M. V., & Pardee, A. B. (2002) · Cell Cycle · doi:10.4161/cc.1.2.108 · Cited by 412
Huang, W.-S., Metcalf, C. A., Sundaramoorthi, R., Wang, Y., Zou, D., Thomas, R. M., Zhu, X., Cai, L., Wen, D., Liu, S., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100395q · Cited by 369
Ebos, J. M. L., Lee, C. R., Christensen, J. G., Mutsaers, A. J., & Kerbel, R. S. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708148104 · Cited by 367
Harris, P. A., Boloor, A., Cheung, M., Kumar, R., Crosby, R. M., Davis-Ward, R. G., Epperly, A. H., Hinkle, K. W., Hunter, R. N., Johnson, J. H., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800566m · Cited by 352
Role of Vegf-Flt Receptor System in Normal and Tumor Angiogenesis
(1995) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60716-2 · Cited by 323
VEGF receptor‐2 Y951 signaling and a role for the adapter molecule TSAd in tumor angiogenesis
Matsumoto, T., Bohman, S., Dixelius, J., Berge, T., Dimberg, A., Magnusson, P., Wang, L., Wikner, C., Qi, J. H., Wernstedt, C., et al. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600709 · Cited by 292
Vascular Endothelial Growth Factor Induction of the Angiogenic Phenotype Requires Ras Activation
Meadows, K. N., Bryant, P., & Pumiglia, K. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m108069200 · Cited by 278
Shu, X., Wu, W., Mosteller, R. D., & Broek, D. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.22.7758-7768.2002 · Cited by 278
Fuh, G., Li, B., Crowley, C., Cunningham, B., & Wells, J. A. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.18.11197 · Cited by 259
Shewchuk, L., Hassell, A., Wisely, B., Rocque, W., Holmes, W., Veal, J., & Kuyper, L. F. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990401t · Cited by 233
Los, M., Roodhart, J. M. L., & Voest, E. E. (2007) · The Oncologist · doi:10.1634/theoncologist.12-4-443 · Cited by 229
Tyrosine kinases as targets in cancer therapy – successes and failures
Traxler, P. (2003) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.7.2.215 · Cited by 226
Lamalice, L., Houle, F., Jourdan, G., & Huot, J. (2004) · Oncogene · doi:10.1038/sj.onc.1207034 · Cited by 224
Ebos, J. M. L., Bocci, G., Man, S., Thorpe, P. E., Hicklin, D. J., Zhou, D., Jia, X., & Kerbel, R. S. (2004) · Molecular Cancer Research · doi:10.1158/1541-7786.315.2.6 · Cited by 211
Scagliotti, G. V., Vynnychenko, I., Park, K., Ichinose, Y., Kubota, K., Blackhall, F., Pirker, R., Galiulin, R., Ciuleanu, T.-E., Sydorenko, O., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.4987 · Cited by 184
Ghosh, S., Sullivan, C. A. W., Zerkowski, M. P., Molinaro, A. M., Rimm, D. L., Camp, R. L., & Chung, G. G. (2008) · Human Pathology · doi:10.1016/j.humpath.2008.06.004 · Cited by 182
p38 MAP Kinase—a molecular switch between VEGF‐induced angiogenesis and vascular hyperpermeability
Issbrücker, K., Martin, H. H., Hippenstiel, S., Springmann, G., Voswinckel, R., Gaumann, A., Breier, G., Drexler, H. C. A., Suttorp, N., & Clauss, M. (2003) · The FASEB Journal · doi:10.1096/fj.02-0329fje · Cited by 179
Aziz, M. A., Serya, R. A. T., Lasheen, D. S., Abdel-Aziz, A. K., Esmat, A., Mansour, A. M., Singab, A. N. B., & Abouzid, K. A. M. (2016) · Scientific Reports · doi:10.1038/srep24460 · Cited by 174
Potashman, M. H., Bready, J., Coxon, A., DeMelfi, DiPietro, L., Doerr, N., Elbaum, D., Estrada, J., Gallant, P., Germain, J., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070034i · Cited by 171
Zeng, H., Sanyal, S., & Mukhopadhyay, D. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103130200 · Cited by 170
Lowe, J., Araujo, J., Yang, J., Reich, M., Oldendorp, A., Shiu, V., Quarmby, V., Lowman, H., Lien, S., Gaudreault, J., et al. (2007) · Experimental Eye Research · doi:10.1016/j.exer.2007.05.008 · Cited by 167
Ségaliny, A. I., Tellez-Gabriel, M., Heymann, M.-F., & Heymann, D. (2015) · Journal of Bone Oncology · doi:10.1016/j.jbo.2015.01.001 · Cited by 164
Seto, T., Higashiyama, M., Funai, H., Imamura, F., Uematsu, K., Seki, N., Eguchi, K., Yamanaka, T., & Ichinose, Y. (2006) · Lung Cancer · doi:10.1016/j.lungcan.2006.02.009 · Cited by 160
VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016)
Peng, F.-W., Liu, D., Zhang, Q., Xu, Y., & Shi, L. (2017) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2017.1344215 · Cited by 160
Activation of p38 Has Opposing Effects on the Proliferation and Migration of Endothelial Cells
McMullen, M. E., Bryant, P. W., Glembotski, C. C., Vincent, P. A., & Pumiglia, K. M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m407060200 · Cited by 159
Structure of a VEGF–VEGF receptor complex determined by electron microscopy
Ruch, C., Skiniotis, G., Steinmetz, M. O., Walz, T., & Ballmer‐Hofer, K. (2007) · Nature Structural & Molecular Biology · doi:10.1038/nsmb1202 · Cited by 155
Shinkai, A., Ito, M., Anazawa, H., Yamaguchi, S., Shitara, K., & Shibuya, M. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.47.31283 · Cited by 155
Machado, V., Peixoto, D., Costa, R., Froufe, H. J. C., Calhelha, R. C., Abreu, R. M. V., Ferreira, I. C. F. R., Soares, R. A., & Queiroz, M. J. R. P. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.08.010 · Cited by 154
Boeuf, F. L., Houle, F., & Huot, J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m405493200 · Cited by 151
Kubo, K., Shimizu, T., Ohyama, S.-I., Murooka, H., Iwai, A., Nakamura, K., Hasegawa, K., Kobayashi, Y., Takahashi, N. K., Takahashi, K., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm030427r · Cited by 150
Abou‐Seri, S. M., Eldehna, W. M., Ali, M. M., & Ella, D. A. A. E. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.10.053 · Cited by 148
Novel 2-chloro-4-anilino-quinazoline derivatives as EGFR and VEGFR-2 dual inhibitors
Barbosa, M. L. D. C., Lima, L. M., Tesch, R., Sant’Anna, C. M. R., Totzke, F., Kubbutat, M. H. G., Schächtele, C., Laufer, S., & Barreiro, E. J. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.10.058 · Cited by 144
Moen, M. D., McKeage, K., Plosker, G. L., & Siddiqui, M. A. A. (2007) · Drugs · doi:10.2165/00003495-200767020-00010 · Cited by 144
Discovery and Evaluation of 2-Anilino-5-aryloxazoles as a Novel Class of VEGFR2 Kinase Inhibitors
Harris, P. A., Cheung, M., Hunter, R., Brown, M. L., Veal, J. M., Nolte, R. T., Wang, L., Liu, W. J., Crosby, R. M., Johnson, J. H., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049538w · Cited by 137
Oncogenic activation of tyrosine kinases
Rodrigues, G. A., & Park, M. (1994) · Current Opinion in Genetics & Development · doi:10.1016/0959-437x(94)90086-8 · Cited by 135
Abdullaziz, M. A., Abdel‐Mohsen, H. T., Kerdawy, A. M. E., Ragab, F. A. F., Ali, M. M., Abu‐Bakr, S. M., Girgis, A. S., & Diwani, H. I. E. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.04.068 · Cited by 122
Comprehensive Dissection of PDGF-PDGFR Signaling Pathways in PDGFR Genetically Defined Cells
Wu, E., Palmer, N., Tian, Z., Moseman, A. P., Galdzicki, M., Wang, X., Berger, B., Zhang, H., & Kohane, I. S. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003794 · Cited by 118
Miettinen, M., Rikala, M.-S., Ryś, J., Lasota, J. P., & Wang, Z.-F. (2012) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e318243555b · Cited by 112
Mechanisms of resistance to vascular endothelial growth factor blockade
Abdullah, S. E., & Perez-Soler, R. (2011) · Cancer · doi:10.1002/cncr.26540 · Cited by 111
Backes, A. C., Zech, B., Felber, B., Klebl, B., & Müller, G. (2008) · Expert Opinion on Drug Discovery · doi:10.1517/17460440802580106 · Cited by 110
Sakai, R., Henderson, J. T., O’Bryan, J. P., Elia, A., Saxton, T. M., & Pawson, T. J. (2000) · Neuron · doi:10.1016/s0896-6273(00)00156-2 · Cited by 109
Role of bevacizumab in colorectal cancer growth and its adverse effects: A review
Pavlidis, T. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i31.5051 · Cited by 106
Eldehna, W. M., Abou‐Seri, S. M., Kerdawy, A. M. E., Ayyad, R. R. A., Hamdy, A. M., Ghabbour, H. A., Ali, M. M., & Ella, D. A. A. E. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.02.029 · Cited by 104
Development And Strategies Of VEGFR-2/KDR Inhibitors
Huang, L., Huang, Z., Bai, Z., Xie, R., Sun, L., & Lin, K. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.121 · Cited by 103
Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays
Mehnert, J. M., McCarthy, M. M., Jilaveanu, L. B., Flaherty, K. T., Aziz, S. A., Camp, R. L., Rimm, D. L., & Kluger, H. M. (2009) · Human Pathology · doi:10.1016/j.humpath.2009.08.016 · Cited by 101
Amaya, H., Tanigawa, N., Lu, C., Matsumura, M., Shimomatsuya, T., Horiuchi, T., & Muraoka, R. (1997) · Cancer Letters · doi:10.1016/s0304-3835(97)00280-2 · Cited by 99
Lafleur, K., Danzhi Huang, A., Zhou, T., Caflisch, A., & Nevado, C. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm9009444 · Cited by 96
1,2,3-Thiadiazole substituted pyrazolones as potent KDR/VEGFR-2 kinase inhibitors
Tripathy, R., Ghose, A. K., Singh, J., Bacon, E. R., Angeles, T. S., Yang, S. X., Albom, M. S., Aimone, L. D., Herman, J. L., & Mallamo, J. P. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.12.054 · Cited by 93
Zhang, H., Gong, F.-H., Ye, J.-Q., Zhang, C., Yue, X.-H., Li, C.-G., Xu, Y., & Sun, L. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.09.039 · Cited by 90
Zhang, Y., Chen, Y., Zhang, D., Wang, L., Lu, T., & Jiao, Y. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01091 · Cited by 88
Cancer Surpasses Heart Disease as Leading Cause of Death for All But the Very Elderly
Twombly, R. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/97.5.330 · Cited by 87
Novel EphB4 Monoclonal Antibodies Modulate Angiogenesis and Inhibit Tumor Growth
Krasnoperov, V. G., Kumar, S. R., Ley, E. J., Li, X., Scehnet, J. S., Liu, R., Zozulya, S., & Gill, P. S. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.090755 · Cited by 85
Oelrichs, R. B., Hh, R., Bernard, O., Ziemiecki, A., & Wilks, A. F. (1993) · PubMed · Cited by 85
Garofalo, A., Goossens, L., Six, P., Lemoine, A., Ravez, S., Farce, A., & Depreux, P. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.01.137 · Cited by 84
Peng, F.-W., Ji, X., Wu, T.-T., Xue, J., Ren, Z., Liu, D., Wang, X., Chen, X.-H., Zhang, J., Xu, Y., et al. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.12.033 · Cited by 83
Ghorab, M. M., Alsaid, M. S., Soliman, A. M., & Ragab, F. A.-F. (2017) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2017.1334650 · Cited by 83
WARNER, A. J., Lopez‐Dee, J., KNIGHT, E. L., Feramisco, J. R., & Prigent, S. A. (2000) · Biochemical Journal · doi:10.1042/0264-6021:3470501 · Cited by 82
Grothey, A. F., George, S., Cutsem, E. V., Blay, J., Sobrero, A. F., & Demetri, G. D. (2014) · The Oncologist · doi:10.1634/theoncologist.2013-0059 · Cited by 80
Novel VEGFR-2 kinase inhibitors identified by the back-to-front approach
Sanphanya, K., Wattanapitayakul, S. K., Phowichit, S., Fokin, V. V., & Vajragupta, O. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.03.042 · Cited by 78
Woo, H. Y., & Heo, J. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.679930 · Cited by 77
Miyamoto, N., Sakai, N., Hirayama, T., Miwa, K., Oguro, Y., Oki, H., Okada, K., Takagi, T., Iwata, H., Awazu, Y., et al. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.01.074 · Cited by 77
Okaniwa, M., Hirose, M., Imada, T., Ohashi, T., Hayashi, Y., Miyazaki, T., Arita, T., Yabuki, M., Kakoi, K., Kato, J., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300126x · Cited by 75
Cortés, F., Debacker, C., Péault, B., & Labastie, M.-C. (1999) · Mechanisms of Development · doi:10.1016/s0925-4773(99)00030-1 · Cited by 71
Luan, X., Gao, C., Zhang, N., Chen, Y., Sun, Q., Tan, C., Liu, H., Jin, Y., & Jiang, Y. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.04.053 · Cited by 70
Claridge, S., Raeppel, F., Granger, M., Bernstein, N., Saavedra, O. M., Zhan, L., Llewellyn, D. B., Wahhab, A., Déziel, R., Rahil, J. F., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.04.009 · Cited by 64
Perspicace, E., Jouan–Hureaux, V., Ragno, R., Ballante, F., Sartini, S., Motta, C. L., Settimo, F. D., Chen, B., Kirsch, G., Schneider, S., et al. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.03.022 · Cited by 63
Matsumoto, S., Miyamoto, N., Hirayama, T., Oki, H., Okada, K., Tawada, M., Iwata, H., Nakamura, K., Yamasaki, S., Miki, H., et al. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.10.028 · Cited by 60
Yang, Y., Shi, L., Zhou, Y., Li, H., Zhu, Z.-W., & Zhu, H. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.09.014 · Cited by 57
Oguro, Y., Cary, D. R., Miyamoto, N., Tawada, M., Iwata, H., Miki, H., Hori, A., & Imamura, S. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.04.042 · Cited by 53
Wang, Y., Wan, S., Li, Z., Fu, Y., Wang, G., Zhang, J., & Wu, X. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.05.054 · Cited by 52
Peng, F.-W., Wu, T.-T., Ren, Z., Xue, J., & Shi, L. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.10.006 · Cited by 48
Gratzinger, D. A., Advani, R. H., Zhao, S., Talreja, N., Tibshirani, R. J., Shyam, R., Horning, S. J., Sehn, L. H., Farinha, P., Briones, J., et al. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07942.x · Cited by 48
Sun, W., Hu, S., Fang, S., & Yan, H. (2018) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2018.04.005 · Cited by 48
Shi, L., Wu, T.-T., Wang, Z., Xue, J., & Xu, Y. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.07.071 · Cited by 47
Gille, J., Heidenreich, R., Pinter, A., Schmitz, J., Boehme, B., Hicklin, D. J., Henschler, R., & Breier, G. (2007) · International Journal of Cancer · doi:10.1002/ijc.22531 · Cited by 43
Gu, W., Dai, Y., Qiang, H., Shi, W., Liao, C., Zhao, F., Huang, W., & Qian, H. (2017) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2017.04.001 · Cited by 43
Zhang, L., Zheng, Q., Yang, Y., Zhou, H.-J., Gong, X., Zhao, S., & Fan, C. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.05.051 · Cited by 42
Design and synthesis of 3,7-diarylimidazopyridines as inhibitors of the VEGF-receptor KDR
Wu, Z., Fraley, M. E., Bilodeau, M. T., Kaufman, M. L., Tasber, E. S., Balitza, A. E., Hartman, G. D., Coll, K. E., Rickert, K. W., Shipman, J. M., et al. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2003.12.007 · Cited by 42
Shi, L., Zhou, J., Wu, J., Cao, J., Shen, Y., Zhou, H., & Li, X. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.03.008 · Cited by 41
In Vitro and In Vivo Activity of Lucitanib in FGFR1/2 Amplified or Mutated Cancer Models
Guffanti, F., Chilà, R., Bello, E., Zucchetti, M., Zangarini, M., Ceriani, L., Ferrari, M., Lupi, M., Jacquet-Bescond, A., Burbridge, M. F., et al. (2016) · Neoplasia · doi:10.1016/j.neo.2016.11.008 · Cited by 41
Gangjee, A., Kurup, S., Ihnat, M. A., et al. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.03.052 · Cited by 40
Luo, G., Tang, Z., Lao, K., Li, X., You, Q., & Xiang, H. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.03.018 · Cited by 40
Axitinib in the Treatment of Metastatic Renal Cell Carcinoma
Ho, T. H., & Jonasch, E. W. (2011) · Future Oncology · doi:10.2217/fon.11.107 · Cited by 39
Tang, Z., Wu, C.-Z., Wang, T., et al. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.04.029 · Cited by 38
Ghorab, M. M., Ragab, F. A.-F., Heiba, H. I., El-Gazzar, M. G., & El-Gazzar, M. G. M. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.03.089 · Cited by 38
Sisko, J. T., Tucker, T. J., Bilodeau, M. T., Buser, C. A., Ciecko, P. A., Coll, K. E., Fernandes, C., Gibbs, W. W., Koester, T. J., Kohl, N. E., et al. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.11.089 · Cited by 36
Yang, C., Guo, Y., Jadlowiec, C. C., Li, X., Lv, W., Model, L. S., Collins, M. J., Kondo, Y., Muto, A., Shu, C., et al. (2013) · Journal of Surgical Research · doi:10.1016/j.jss.2013.01.009 · Cited by 36
Zhang, L., Shan, Y., Ji, X., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.20065 · Cited by 36
Notch signaling in the pathologic adult brain
Mathieu, P., Adami, P. V. M., & Morelli, L. (2013) · BioMolecular Concepts · doi:10.1515/bmc-2013-0006 · Cited by 34
Oguro, Y., Miyamoto, N., Takagi, T., Okada, K., Awazu, Y., Miki, H., Hori, A., Kamiyama, K., & Imamura, S. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.08.042 · Cited by 34
Mirshafiey, A., Ghalamfarsa, G., Asghari, B., & Azizi, G. (2014) · Europe PMC (PubMed Central) · Cited by 32
Qiang, H., Gu, W., Huang, D., Shi, W., Qiu, Q., Dai, Y., Huang, W., & Qian, H. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.03.061 · Cited by 32
Nakamura, H., Sasaki, Y., Uno, M., Yoshikawa, T., Asano, T., Ban, H. S., Fukazawa, H., Shibuya, M., & Uehara, Y. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.07.075 · Cited by 30
Aziz, Y. M. A., Said, M. M., Elshihawy, H. A., & Abouzid, K. A. M. (2015) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2015.03.004 · Cited by 30
Gangjee, A., Namjoshi, O. A., Yu, J., Ihnat, M. A., Thorpe, J. E., & Warnke, L. A. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.04.019 · Cited by 30
Nintedanib: A Novel Therapeutic Approach for Idiopathic Pulmonary Fibrosis
Dimitroulis, J. (2014) · Respiratory Care · doi:10.4187/respcare.03023 · Cited by 30
Miyamoto, N., Oguro, Y., Takagi, T., Iwata, H., Miki, H., Hori, A., & Imamura, S. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.10.004 · Cited by 25
Tan, S., Han, K., Li, Q., Tong, L., Yang, Y., Chen, Z., Xie, H., Ding, J., Qian, X. H., & Xu, Y. F. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.07.068 · Cited by 24
Salerno, S., Marini, A. M., Fornaciari, G., Simorini, F., Motta, C. L., Taliani, S., Sartini, S., Settimo, F. D., García‐Argáez, A. N., Gia, O. M., et al. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.08.027 · Cited by 22
Ding, L., Tang, F. S., Huang, W., Qiu, J. J., Shen, H. M., & Wei, P. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.08.037 · Cited by 21
Evolution of a New Class of VEGFR-2 Inhibitors from Scaffold Morphing and Redesign
Mainolfi, N., Karki, R. G., Liu, F., et al. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5b00486 · Cited by 21
Choquette, D. M., Teffera, Y., Polverino, A. J., & Harmange, J.-C. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.05.114 · Cited by 19
Zhao, X., Liu, D., Luan, S., Hu, G., Lv, J.-L., Jing, Y., & Zhao, L. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.10.009 · Cited by 19
Jin, F., Gao, D., Wu, Q., Liu, F., Chen, Y., Tan, C., & Jiang, Y. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.07.026 · Cited by 19
Evaluation of EphA2 and EphB4 as Targets for Image-Guided Colorectal Cancer Surgery
Stammes, M. A., Prevoo, H. A. J. M., Horst, M. C. T., Groot, S. A., van de Velde, C. J. �., Chan, A. B., de Geus‐Oei, L., Kuppen, P. J. K., Vahrmeijer, A. L., Pasquale, E. B., et al. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020307 · Cited by 18
Ibrahim, H. A., Awadallah, F. M., Refaat, H. M., & Amin, K. M. (2018) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0174 · Cited by 18
Guo, S., Laronna, S., Tanisha, Z., & Ruben, R. J. (2012) · InTech eBooks · doi:10.5772/27370 · Cited by 16
Underiner, T. L., Ruggeri, B., Aimone, L. D., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.02.069 · Cited by 9
Gao, G., Li, M., Lv, Y., Cao, S., Tong, L., Wei, L., Ding, J., Xie, H., & Duan, W. (2015) · Chinese Chemical Letters · doi:10.1016/j.cclet.2015.10.004 · Cited by 9
Yen, C., Bai, L., Cheng, R., Hsiao, F., & Orlando, M. (2018) · Journal of Cancer Research and Practice · doi:10.1016/j.jcrpr.2018.03.001 · Cited by 7
Cited by
Angiogenic signaling pathways and anti-angiogenic therapy for cancer
Liu, Z.-L., Chen, H.-H., Zheng, L.-L., Sun, L.-P., & Shi, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01460-1 · Cited by 1,300
Nath, J., Paul, R., Ghosh, S. K., Paul, J., Singha, B., & Debnath, N. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118189 · Cited by 71
Singh, D. P., Pathak, R., Chintalaramulu, N., Pandit, A., Kumar, A., Ebenezer, P. J., Kumar, S., Duplooy, A., White, M. E., Jambunathan, N., et al. (2024) · Cancer Gene Therapy · doi:10.1038/s41417-024-00821-4 · Cited by 12
Pro-Angiogenetic Effects of Purified Extracts from Helix aspersa during Zebrafish Development
Zizioli, D., Mastinu, A., Muscò, A., Bonini, S. A., Finazzi, D., Avisani, R., Kron Morelli, G. B., Pecorelli, S., & Memo, M. (2022) · Current Issues in Molecular Biology · doi:10.3390/cimb44080232 · Cited by 4
Metadata
- Authors
- Modi, S. J., & Kulkarni, V. M.
- Venue
- Medicine in Drug Discovery
- Publisher
- Elsevier BV
- Published
- 2019-06
- Volume
- 2
- Pages
- 100009
- ISSN
- 2590-0986 (ISSN-L)
- OpenAlex
- W2981810096
- Cited by
- 320
- References
- 152
- FWCI
- 6.37
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.